Study on Genetic Changes in Breast Cancer Patients
Author Information
Author(s): Launonen V, Laake K, Huusko P, Niederacher D, Beckmann M W, Barkardottir R B, Geirsdottir E K, Gudmundsson J, Rio P, Bignon Y-J, Seitz S, Scherneck S, Bièche I, Champème M-H, Birnbaum D, White G, Varley J, Sztán M, Olah E, Osorio A, Benitez J, Spurr N, Velikonja N, Peterlin B, Borg Å, Cleton-Jansen A-M, Devilee P, Bloigu R, Lidereau R, Børresen-Dale A-L, Winqvist R, the Breast Cancer Somatic Genetics Consortium
Primary Institution: Departments of Clinical Genetics, Mathematical Science/Statistics, Oncology and Radiotherapy, University of Oulu/Oulu University Hospital, Oulu, Finland
Hypothesis
Is there a relationship between loss of heterozygosity (LOH) at the APOC3 locus and clinical variables in breast cancer patients?
Conclusion
LOH for APOC3 was found in 42% of the studied tumors, but it was not significantly associated with any clinical variables.
Supporting Evidence
- 42% of the studied tumors showed loss of heterozygosity at the APOC3 locus.
- The study involved a large cohort of 766 breast cancer patients.
- LOH was not significantly associated with cancer-specific survival time.
Takeaway
The study looked at a gene related to breast cancer and found that many tumors had a specific genetic change, but it didn't seem to affect how patients did.
Methodology
The study examined the occurrence of APOC3 LOH in a cohort of breast cancer patients and evaluated its effect on clinical behavior.
Limitations
The study did not find significant associations with clinical variables, suggesting limitations in the relationship between LOH and patient outcomes.
Participant Demographics
The study involved 766 breast cancer patients from multiple European centers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website